JPMorgan lowered the firm’s price target on Evolent Health (EVH) to $12 from $13 and keeps an Overweight rating on the shares. Evolent Health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback